A phase 1 dose escalation and dose expansion study for LNCB74, a B7-H4 targeted antibody drug conjugate, as monotherapy in participants with advanced solid tumors.

Authors: Michael M Song, Anthony W. Tolcher, Martin E. Gutierrez, Emese Zsiros, Siqing Fu, Joyce F. Liu, Daniel Morgensztern, Stephanie Kordahi, Christine Nietubicz, Emilia Alina Barbu, Aaron Morawski, Shannon Kahan, Priyanka Kothari, Dallas Flies, Shanmugam Panneer Selvam, Stephen Slocum, Rodrigo Ruiz-Soto, Solomon Langermann, Udayan Guha, Daruka Mahadevan

Published: 2025-05-28

DOI: 10.1200/jco.2025.43.16_suppl.tps3167

Source: Full article

---

Abstract

TPS3167